Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER+ Breast Cancer”

972 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 972 results

Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Testing effectiveness (Phase 2)UnknownNCT01266213
What this trial is testing

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women

Who this might be right for
Metastatic Breast CancerEstrogen Receptor Positive TumorBreast Cancer Nos Premenopausal
Samsung Medical Center 147
Early research (Phase 1)Ended earlyNCT00972023
What this trial is testing

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Who this might be right for
Breast Cancer
Barbara Ann Karmanos Cancer Institute 1
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Early research (Phase 1)Active Not RecruitingNCT04188548
What this trial is testing

LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+1 more
Eli Lilly and Company 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410559
What this trial is testing

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 189
Testing effectiveness (Phase 2)Study completedNCT00755885
What this trial is testing

Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Research UK 77
Testing effectiveness (Phase 2)Looking for participantsNCT06000917
What this trial is testing

Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

Who this might be right for
Breast CancerNeoadjuvant
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 62
Early research (Phase 1)Active Not RecruitingNCT05509790
What this trial is testing

LY3484356 in Chinese Participants With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 17
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Testing effectiveness (Phase 2)Study completedNCT01234857
What this trial is testing

Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Who this might be right for
Breast Cancer
Merck Sharp & Dohme LLC 115
Testing effectiveness (Phase 2)Looking for participantsNCT07159451
What this trial is testing

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 140
Testing effectiveness (Phase 2)Ended earlyNCT00517361
What this trial is testing

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
University of Chicago 11
Not applicableEnded earlyNCT02149173
What this trial is testing

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Who this might be right for
Estrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
University of Washington 29
Testing effectiveness (Phase 2)Study completedNCT01421472
What this trial is testing

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Who this might be right for
ER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients
Merrimack Pharmaceuticals 196
Not applicableStudy completedNCT00115505
What this trial is testing

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

Who this might be right for
Breast Carcinoma
Alliance for Clinical Trials in Oncology 307
Not applicableStudy completedNCT03981705
What this trial is testing

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Who this might be right for
TN ER-/PR-/HER2- Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer+1 more
Masonic Cancer Center, University of Minnesota 8
Testing effectiveness (Phase 2)Looking for participantsNCT07340541
What this trial is testing

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Who this might be right for
Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer+2 more
UNC Lineberger Comprehensive Cancer Center 700
Testing effectiveness (Phase 2)Study completedNCT01377324
What this trial is testing

Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites

Who this might be right for
Metastatic Breast Cancer
University Medical Center Groningen 16
Testing effectiveness (Phase 2)Ended earlyNCT02395627
What this trial is testing

Reversing Therapy Resistance With Epigenetic-Immune Modification

Who this might be right for
Breast Neoplasms
University of California, San Francisco 38
Load More Results